Tue, 04-Aug-2020
Wednesday 22 Jul 2020 , 1:21 pm

Mylan Gets Indian Regulatory Approval for Tuberculosis Drug

Pretomanid has been approved as part of a three-drug, six-month all-oral regimen for the treatment of highly drug-resistant forms of tuberculosis. The three-drug combination also consists of linezolid and J&J’s bedaquiline.
By SIN Bureau
Share at:

Drugmaker Mylan NV said on Wednesday it has received Indian regulatory approval to make tuberculosis treatment pretomanid available in a country that accounts for a quarter of the world’s cases.

Mylan will initially make a donation of 400 treatment courses of pretomanid under the Indian government’s National Tuberculosis Elimination Program (NTEP) and will provide commercial access at $364 for a six-month treatment course.

“The Drug Controller General of India has approved the anti-tuberculosis drug pretomanid for conditional access under the NTEP,” Mylan said to Reuters in an emailed statement.

New treatments against tuberculosis have been sparse, with pretomanid being only the third new drug developed for drug-resistant forms of the disease to be approved in more than 40 years, after Johnson & Johnson’s bedaquiline and Otsuka Pharmaceutical Co Ltd’s delamanid.

The approval comes amid fears the coronavirus outbreak has derailed global efforts to curtail the spread of tuberculosis, a bacterial infection that mainly affects a patient’s lungs.

Between 2020 and 2025, an additional 1.4 million tuberculosis deaths could be registered as a direct consequence of the COVID-19 pandemic, the World Health Organization said.

Pretomanid has been approved as part of a three-drug, six-month all-oral regimen for the treatment of highly drug-resistant forms of tuberculosis. The three-drug combination also consists of linezolid and J&J’s bedaquiline.

Not-for-profit TB Alliance granted a non-exclusive license to Mylan to manufacture and sell pretomanid in April last year. Pretomanid as part of the three-drug combination was approved by the U.S. Food and Drug Administration in August last year.

Read Here




Neha Mule

Neha writes articles on sectors including medicine, food, materials, and science & technology. A qualified statistician, she has the ability to observe and analyze the trends in global markets and write compelling articles that help CXOs in decision making. She is a bookworm and loves to read fiction, lifestyle, science and technology. Neha comes with 6 years of experience in content writing and editing that involves blog writing, preparation of study materials and OERs.

More from Neha Mule

Smart News, Updates and Insights Drive Smarter Decisions

Smart Industry News is a one stop shop of industry news across the globe. We have a team of experts who provides latest updates on industry news to our readers daily. The news available on our website is general information and does not provide our customers with any legal or professional advice specific to any industry...

sales@smartindustrynews.com
media@smartindustrynews.com

Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved